Skip to main content

Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation

Psychopharmacology volume 234, pages 2919–2927 (2017)Cite this article

Abstract

Background

Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear.

Objective

The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia.

Methods

Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level.

Results

Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = −0.387; p = 0.020).

Conclusions

Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  • Alves CM, Silva DA, Azzolini AE, Marzocchi-Machado CM, Carvalho JV, Pajuaba AC, Lucisano-Valim YM, Chammas R, Liu FT, Roque-Barreira MC, Mineo JR (2010) Galectin-3 plays a modulatory role in the life span and activation of murine neutrophils during early Toxoplasma gondii infection. Immunobiology 215:475–485

    CAS  Article  PubMed  Google Scholar 

  • Andreasen NC (1991) Assessment issues and the cost of schizophrenia. Schizophr Bull 17:475–481

    CAS  Article  PubMed  Google Scholar 

  • Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A, Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M (2010) Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 67:589–597

    CAS  Article  PubMed  Google Scholar 

  • Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810

    CAS  PubMed  Google Scholar 

  • Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, Bloomfield MA, Bonoldi I, Kalk N, Turkheimer F, McGuire P, de Paola V, Howes OD (2016) Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. Am J Psychiatry 173:44–52

    Article  PubMed  Google Scholar 

  • Brewer CF (2004) Thermodynamic binding studies of galectin-1, -3 and -7. Glycoconj J 19:459–465

    Article  Google Scholar 

  • Brook S, Walden J, Benattia I, Siu CO, Romano SJ (2005) Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology 178:514–523

    CAS  Article  PubMed  Google Scholar 

  • Burguillos MA, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, Santiago M, Viceconte N, Oliva-Martin MJ, Osman AM, Salomonsson E, Amar L, Persson A, Blomgren K, Achour A, Englund E, Leffler H, Venero JL, Joseph B, Deierborg T (2015) Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep

  • Calcia MA, Bonsall DR, Bloomfield PS, Selvaraj S, Barichello T, Howes OD (2016) Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology 233:1637–1650

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM, Yu LG (2013) Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res 19:1693–1704

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Chen SS, Sun LW, Brickner H, Sun PQ (2015) Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference. Cell Immunol 294:44–53

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Davalieva K, Maleva Kostovska I, Dwork AJ (2016) Proteomics research in schizophrenia. Front Cell Neurosci 10:18

    Article  PubMed  PubMed Central  Google Scholar 

  • de Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A (2015) Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood) 240:1019–1028

    Article  Google Scholar 

  • de Waard A, Hickman S, Kornfeld S (1976) Isolation and properties of beta-galactoside binding lectins of calf heart and lung. J Biol Chem 251:7581–7587

    PubMed  Google Scholar 

  • Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM (2016) Galectin-3 in renal pathology: more than just an innocent bystander. Am J Nephrol 43:305–317

    CAS  Article  PubMed  Google Scholar 

  • Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N, Velligan D, Walss-Bass C (2013) Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 151:29–35

    Article  PubMed  Google Scholar 

  • Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616–635

    CAS  Article  PubMed  Google Scholar 

  • Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679–1700

    CAS  Article  PubMed  Google Scholar 

  • Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, Henderson DC (2010) Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 118:211–217

    Article  PubMed  Google Scholar 

  • Fryk E, Sundelin JP, Strindberg L, Pereira MJ, Federici M, Marx N, Nystrom FH, Schmelz M, Svensson PA, Eriksson JW, Boren J, Jansson PA (2016) Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. Metabolism 65:998–1006

    CAS  Article  PubMed  Google Scholar 

  • Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F (2013) Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 106:541–546

    Article  PubMed  Google Scholar 

  • Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, Sorcini M, Di Mario U, Pesce C, Pugliese G (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18:1773–1775

    CAS  PubMed  Google Scholar 

  • Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Horslev-Petersen K, Junker P (2015) Within-day variation and influence of physical exercise on circulating galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol 82:70–75

    CAS  Article  PubMed  Google Scholar 

  • Iwamoto M, Taguchi C, Sasaguri K, Kubo KY, Horie H, Yamamoto T, Onozuka M, Sato S, Kadoya T (2010) The galectin-1 level in serum as a novel marker for stress. Glycoconj J 27:419–425

    CAS  Article  PubMed  Google Scholar 

  • Kajitani K, Kobayakawa Y, Nomaru H, Kadoya T, Horie H, Nakabeppu Y (2014) Characterization of galectin-1-positive cells in the mouse hippocampus. Neuroreport 25:171–176

    CAS  Article  PubMed  Google Scholar 

  • Kajitani K, Nomaru H, Ifuku M, Yutsudo N, Dan Y, Miura T, Tsuchimoto D, Sakumi K, Kadoya T, Horie H, Poirier F, Noda M, Nakabeppu Y (2009) Galectin-1 promotes basal and kainate-induced proliferation of neural progenitors in the dentate gyrus of adult mouse hippocampus. Cell Death Differ 16:417–427

    CAS  Article  PubMed  Google Scholar 

  • Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2:258–270

    Article  PubMed  PubMed Central  Google Scholar 

  • Khandaker GM, Dantzer R (2016) Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology 233:1559–1573

    CAS  Article  PubMed  Google Scholar 

  • Kim YK, Kim L, Lee MS (2000) Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44:165–175

    CAS  Article  PubMed  Google Scholar 

  • Koike S, Kayama T, Arai M, Horiuchi Y, Kobori A, Miyashita M, Itokawa M, Ogasawara Y (2015) Characterization of modified proteins in plasma from a subtype of schizophrenia based on carbonyl stress: protein carbonyl is a possible biomarker of psychiatric disorders. Biochem Biophys Res Commun 467:361–366

    CAS  Article  PubMed  Google Scholar 

  • Kouidrat Y, Amad A, Arai M, Miyashita M, Lalau JD, Loas G, Itokawa M (2015) Advanced glycation end products and schizophrenia: a systematic review. J Psychiatr Res 66-67:112–117

    Article  PubMed  Google Scholar 

  • Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9:305–328

    CAS  PubMed  Google Scholar 

  • Lai CY, Scarr E, Udawela M, Everall I, Chen WJ, Dean B (2016) Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. World J Psychiatry 6:102–117

    Article  PubMed  PubMed Central  Google Scholar 

  • Leboyer M, Oliveira J, Tamouza R, Groc L (2016) Is it time for immunopsychiatry in psychotic disorders? Psychopharmacology 233:1651–1660

    CAS  Article  PubMed  Google Scholar 

  • Lee KU, Jeon YW, Lee HK, Jun TY (2009) Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum Psychopharmacol 24:447–452

    CAS  Article  PubMed  Google Scholar 

  • Levi G, Teichberg VI (1984) The distribution of electrolectin in mouse: genetic and ontogenic variations. Biochem Biophys Res Commun 119:801–806

    CAS  Article  PubMed  Google Scholar 

  • Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29–41

    CAS  Article  PubMed  Google Scholar 

  • Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Monji A, Kato T, Kanba S (2009) Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265

    CAS  Article  PubMed  Google Scholar 

  • Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363:2063–2072

    Article  PubMed  Google Scholar 

  • Nakahara S, Raz A (2006) On the role of galectins in signal transduction. Methods Enzymol 417:273–289

    CAS  Article  PubMed  Google Scholar 

  • Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Nasef NA, Mehta S, Ferguson LR (2017) Susceptibility to chronic inflammation: an update. Arch Toxicol 91:1131–1141

    CAS  Article  PubMed  Google Scholar 

  • Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337–345

    CAS  Article  PubMed  Google Scholar 

  • Ouyang J, Plutschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA (2013) Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 121:3431–3433

    CAS  Article  PubMed  Google Scholar 

  • Overall JE, Gorham DR (1988) The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 24:97–99

    Google Scholar 

  • Shafer A (2005) Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 17:324–335

    Article  PubMed  Google Scholar 

  • Sirko S, Irmler M, Gascon S, Bek S, Schneider S, Dimou L, Obermann J, De Souza PD, Poirier F, Beckers J, Hauck SM, Barde YA, Gotz M (2015) Astrocyte reactivity after brain injury-: the role of galectins 1 and 3. Glia 63:2340–2361

    Article  PubMed  PubMed Central  Google Scholar 

  • Smit AJ, Lutgers HL (2004) The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11:2767–2784

    CAS  Article  PubMed  Google Scholar 

  • Stanta JL, Saldova R, Struwe WB, Byrne JC, Leweke FM, Rothermund M, Rahmoune H, Levin Y, Guest PC, Bahn S, Rudd PM (2010) Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res 9:4476–4489

    CAS  Article  PubMed  Google Scholar 

  • Telford JE, Bones J, McManus C, Saldova R, Manning G, Doherty M, Leweke FM, Rothermundt M, Guest PC, Rahmoune H, Bahn S, Rudd PM (2012) Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins. J Proteome Res 11:3743–3752

    CAS  Article  PubMed  Google Scholar 

  • Tomasik J, Schwarz E, Guest PC, Bahn S (2012) Blood test for schizophrenia. Eur Arch Psychiatry Clin Neurosci 262(Suppl 2):S79–S83

    Article  PubMed  Google Scholar 

  • Tourjman V, Kouassi E, Koue ME, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, Potvin S (2013) Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res 151:43–47

    Article  PubMed  Google Scholar 

  • Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP (2016) Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry 21:1009–1026

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Tunca Z, Kivircik Akdede B, Ozerdem A, Alkin T, Polat S, Ceylan D, Bayin M, Cengizcetin Kocuk N, Simsek S, Resmi H, Akan P (2015) Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry 30:198–204

    CAS  Article  PubMed  Google Scholar 

  • Tynan RJ, Beynon SB, Hinwood M, Johnson SJ, Nilsson M, Woods JJ, Walker FR (2013) Chronic stress-induced disruption of the astrocyte network is driven by structural atrophy and not loss of astrocytes. Acta Neuropathol 126:75–91

    CAS  Article  PubMed  Google Scholar 

  • van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820–822

    Article  PubMed  Google Scholar 

  • Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S (2013) Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neuro-Oncol 115:9–17

    CAS  Article  Google Scholar 

  • Walker AR, Bonomi R, Popov V, Gelovani JG, Andres Cisneros G (2017) Investigating carbohydrate based ligands for galectin-3 with docking and molecular dynamics studies. J Mol Graph Model 71:211–217

    CAS  Article  PubMed  Google Scholar 

  • Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW (2010) Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35:2274–2283

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Xiu MH, Yang GG, Tan YL, Chen DC, Tan SP, Wang ZR, Yang FD, Okusaga O, Soares JC, Zhang XY (2014) Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology. Schizophr Res 156:9–14

    Article  PubMed  Google Scholar 

  • Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A (2015) Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Investig 38:527–533

    CAS  Article  Google Scholar 

Download references

Acknowledgments

The authors thank all of the staff in the affiliated hospitals of Kyushu University (Hakomatsu Hospital, Kawazoe Hospital, and Imajuku Hospital) for recruiting the participants.

Author information

Authors and Affiliations

  1. Counseling and Health Center, Faculty of Arts and Science, Kyushu University, 6-1 Kasuga-koen, Kasuga, Fukuoka, 816-8580, Japan

    Kosuke Kajitani

  2. Department of Psychiatry, Hakomatsu Hospital, 1-3-9 Higashi-ku, Hakomatsu, Fukuoka, 812-0061, Japan

    Kosuke Kajitani & Kazuyuki Yanagimoto

  3. Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Higashi-ku, Maidashi, Fukuoka, 815-8582, Japan

    Yusaku Nakabeppu

Authors
  1. Kosuke Kajitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuyuki Yanagimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusaku Nakabeppu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kosuke Kajitani.

Ethics declarations

This study was approved by the Ethics Committee of the Faculty of Arts and Science, Kyushu University, Japan. Informed written consent was obtained from each participant after they were given information about the study.

Funding

This study was funded by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and the Japan Society for the Promotion of Science (25870494 to K. Kajitani).

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kajitani, K., Yanagimoto, K. & Nakabeppu, Y. Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation. Psychopharmacology 234, 2919–2927 (2017). https://doi.org/10.1007/s00213-017-4683-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-017-4683-9

Keywords

  • Galectin-1
  • Galectin-3
  • Schizophrenia
  • Neuroinflammation
  • Serum
  • Brief Psychiatry Rating Scale